Equities research analysts expect that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will report earnings per share of $0.67 for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Endo International PLC’s earnings, with estimates ranging from $0.62 to $0.71. Endo International PLC posted earnings per share of $1.01 during the same quarter last year, which indicates a negative year-over-year growth rate of 33.7%. The business is scheduled to issue its next quarterly earnings report after the market closes on Thursday, November 9th.

On average, analysts expect that Endo International PLC will report full-year earnings of $3.51 per share for the current fiscal year, with EPS estimates ranging from $3.35 to $3.61. For the next financial year, analysts anticipate that the firm will post earnings of $3.04 per share, with EPS estimates ranging from $2.46 to $3.76. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Endo International PLC.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million during the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The business’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.86 earnings per share.

Several analysts have recently commented on the company. Royal Bank Of Canada set a $9.00 target price on Endo International PLC and gave the stock a “hold” rating in a research report on Thursday, August 10th. Cowen and Company reaffirmed a “hold” rating and issued a $16.00 target price on shares of Endo International PLC in a research report on Thursday, August 10th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research report on Tuesday, August 8th. Deutsche Bank AG set a $13.00 target price on Endo International PLC and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $11.00 target price (down previously from $15.00) on shares of Endo International PLC in a research report on Friday, August 11th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have assigned a buy rating to the company’s stock. Endo International PLC currently has a consensus rating of “Hold” and an average target price of $12.64.

In other Endo International PLC news, COO Terrance J. Coughlin acquired 20,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were acquired at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the purchase, the chief operating officer now owns 181,369 shares of the company’s stock, valued at approximately $1,396,541.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Paul Campanelli acquired 6,500 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was acquired at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the purchase, the chief executive officer now directly owns 213,620 shares of the company’s stock, valued at approximately $1,647,010.20. The disclosure for this purchase can be found here. Insiders bought 36,000 shares of company stock worth $279,460 over the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. HL Financial Services LLC increased its stake in shares of Endo International PLC by 1.0% in the second quarter. HL Financial Services LLC now owns 52,800 shares of the company’s stock worth $590,000 after purchasing an additional 500 shares during the period. Amalgamated Bank increased its stake in shares of Endo International PLC by 2.0% in the first quarter. Amalgamated Bank now owns 32,357 shares of the company’s stock worth $361,000 after purchasing an additional 619 shares during the period. Meeder Asset Management Inc. increased its stake in shares of Endo International PLC by 1.4% in the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock worth $544,000 after purchasing an additional 677 shares during the period. Capstone Asset Management Co. increased its stake in shares of Endo International PLC by 3.1% in the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock worth $358,000 after purchasing an additional 960 shares during the period. Finally, Arizona State Retirement System increased its stake in shares of Endo International PLC by 1.5% in the second quarter. Arizona State Retirement System now owns 83,700 shares of the company’s stock worth $935,000 after purchasing an additional 1,200 shares during the period. Institutional investors and hedge funds own 90.71% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/10/21/analysts-anticipate-endo-international-plc-endp-to-announce-0-67-earnings-per-share.html.

Shares of Endo International PLC (ENDP) traded down 2.03% during midday trading on Friday, reaching $7.72. The company’s stock had a trading volume of 3,101,745 shares. Endo International PLC has a 52 week low of $7.40 and a 52 week high of $21.87. The stock’s market capitalization is $1.72 billion. The stock has a 50-day moving average price of $8.52 and a 200 day moving average price of $10.43.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get a free copy of the Zacks research report on Endo International PLC (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.